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1. Introduction 
In T2DM, macro- and microvascular complications represent the major cause for morbi-
/mortality, decreased quality of life and healthcare costs. Current guidelines for standards 
of care in T2DM emphasize the significance of multifactorial intervention on standard 
modifiable variables, in order to achieve recommended levels of blood glucose, LDL-C and 
blood pressure. T2DM patients achieving such targets represent a minority. Many of those 
not meeting those targets are exposed to high residual vascular risk (RVR) to develop 
incident micro- and macrovascular events and/or to suffer from progression of existing 
complications. Determining RVR in T2DM patients is of major relevance, as a substantial 
fraction of it is modifiable, including a lipid-related fraction, associated with both LDL and 
non-LDL lipids and lipoproteins. Atherogenic dyslipidemia (AD) is characterized by raised 
fasting triglycerides and low HDL-C. AD contributes to RVR of micro- and macrovascular 
disease in T2DM, even when LDL-C and/or hyperglycemia are controlled. The presence of 
a metabolic syndrome, or its score, is an additional means to capture modifiable components 
of RVR for micro- and macroangiopathy. AD is best prevented and addressed by 
therapeutic lifestyle changes, fibrates, or nicotinic acid. In the ACCORD Lipid trial, RVR of 
macrovascular events was high despite background simvastatin, and was substantially 
decreased in patients with AD following bitherapy with fenofibrate plus simvastatin. In 
FIELD and/or ACCORD trials, fenofibrate also decreased RVR of retinopathy progression, 
irrespective of baseline lipids, reduced albuminuria incidence and risk of diabetes-related 
lower-limb amputations. These data suggest a wider role for fenofibrate in the management 
of multisite microvessel RVR in T2DM. As regards other anti-dyslipidaemic drugs, ongoing 
trials will establish whether targeting low HDL-C with niacin reduces RVR in high-risk 
T2DM patients.  
2. Standards of care in T2DM and target attainments 
In type 2 diabetes mellitus (T2DM), vascular complications represent the major cause for 
morbi-/mortality, decreased quality of life and healthcare costs. These chronic, long-term 
complications arise in the setting of elevated residual vascular risk (RVR) factors. These 
factors may not only damage macrovessels, leading to premature-onset coronary artery 
disease (CAD), cerebrovascular disease (transient ischemic attack (TIA) and/or stroke), or 
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peripheral arterial disease (PAD), but also affect microvessels leading to “diabetic 
complications”, i.e. diabetes-specific long-term complications of chronic hyperglycemia: 
retinopathy, nephropathy or neuropathy. Certain vascular diabetic complications such as 
PAD, TIA/stroke, nephropathy or erectile dysfunction may arise from a combination of 
macro- and microangiopathies [1-6].  
Low-density lipoprotein cholesterol (LDL-C) 
Due to the overall efficacy of statins, and the relatively low baseline level of LDL-C in 
T2DM, LDL-C may be considered as the easiest-modifiable single parameter in diabetic 
patients [4,5,7-15]. However, in the recent Centralized Pan-European survey on the under-
treatment of hypercholesterolaemia (CEPHEUS), a primary care survey from 8 European 
countries, under-treatment of hypercholesterolaemia was highly prevalent, with low total 
and LDL-C target attainment observed across countries [16,17]. In CEPHEUS, patients with 
the highest CV risk were T2DM patients with established cardiovascular disease (CVD) (i.e. 
patients in true secondary CV prevention). Yet, these highest-risk patients achieved the 
lowest level of LDL-C target attainment, with only 27% attaining the <70 mg/dL target. 
Moreover, only 58% of T2DM patients without CVD achieved LDL-C target <100 mg/dL. 
Eight modifiable variables were associated with LDL-C target attainment in CEPHEUS [17]: 
1. normal body mass index;  
2. being a non-smoker; 
3. not having a metabolic syndrome (MetS) phenotype; 
4. current treatment with a statin; 
5. belonging to a medium-high CVD risk category; 
6. good treatment adherence; 
7. high patient’s awareness of his/her current LDL-C level; and/or 
8. frequency of cholesterol reviews.  
Six non-modifiable factors were also associated with LDL-C target attainment: 
1. age >70 years; 
2. male gender; 
3. history of diabetes; 
4. history of hypertension; 
5. absence of PAD; and/or 
6. receiving LLD for secondary prevention.  
Blood pressure (BP) 
Controlling BP values in T2DM is of paramount importance, as it improves both macro- and 
microvascular outcomes. Such control is nevertheless challenging, as in the common form of 
T2DM, associated with the MetS and insulin resistance (IR), hypertension is not only highly 
prevalent, but also responds poorly to BP-lowering monotherapy intervention, and often 
requires multiple BP-lowering therapies on top of therapeutic lifestyle changes (TLC). In a 
recent study, only 16% of hypertensive T2DM treated with BP-lowering drug(s) in a tertiary-
care setting achieved target BP <130<80 mmHg (<125<75 mmHg in case of proteinuria) [18].  
Glycemic control and glycated haemoglobin (HbA1c) 
Maintaining HbA1c at target is an additional and constant challenge in T2DM, due to 
relentless loss of β-cell function over time and perpetual requirement for progressive 
stepping-up of glucose-lowering therapies [3,19,20]. Despite a large choice of oral and 
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parenteral therapies to lower blood glucose, target attainment as regards glucose control, or 
that of its surrogate HbA1c, remains suboptimal. Among U.S. adults with diabetes in 1999–
2002, only 49.8% had an HbA1c <7.0% [19], a proportion similar to that found 10 years later 
in the OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment 
(OPTIMISE) trial [21].  
Multifactorial intervention 
Current guidelines for standards of care in T2DM emphasize the significance of 
multifactorial intervention on major modifiable RFs to achieve recommended levels of 
glucose, LDL-C and BP [12-15]. In the Steno study, a multifactorial intervention aimed at 
achieving recommended levels of critical indicators, including HbA1c as surrogate for 
contemporary glucose exposure, LDL-C and systolic BP (SBP), was highly effective in 
reducing (micro)vascular complications [22-24].  
As each of these three major modifiable targets have distinct determinants, natural histories 
and responses to TLC or pharmacotherapy, it comes to no surprise that only a fraction of 
T2DM patients will reach all three targets in synchrony in real-life conditions, leaving a 
majority of T2DM patients exposed to incident micro-/macrovascular events over time, or 
to progression of existing complications [18,21].  
Many factors associated with failure to meet critical targets (HbA1c, LDL-C. SBP) in T2DM 
represent previously identified barriers to chronic diseases management:    
• age;  
• disease duration; 
• ethnicity; 
• hyperglycaemia, hypertension and dyslipidaemia are mostly asymptomatic conditions, 
both in primary or secondary prevention; 
• chronic disease misrepresentation; 
• faulty perception of risk related to metabolic diseases is frequently observed among 
many T2DM patients, especially from ethnic minorities; 
• patients are often poorly compliant to TLC; 
• impractical, conflicting, or competing guidelines; 
• many patients are poorly adherent to prescribed treatment regimens and/or to self-
monitoring of blood glucose; 
• fear of hypoglycaemia; 
• concerns about weight gain;  
• fear, misperception of the natural history of T2DM and of the risk/benefit ratio of 
adding exogenous insulin; 
• delaying tactics at the time when lifelong insulin supplementation is deemed necessary 
(insulinophobia);  
• reluctance to resort to subcutaneous injections or to perform capillary blood glucose 
self-testing; 
• variations among patients in pharmacological response to antidiabetic, lipid-lowering 
and/or BP-lowering drugs; 
• reluctance of physicians and patients to increasing drug dosage or to switching drugs 
within classes, or to resorting to combined therapies; 
• complex treatment schemes and side-effects; 
• wrong perception of potential side-effects; 
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• insufficient counseling; 
• physicians and healthcare providers inertia delaying diagnosis or stepping-up of 
successive interventions; 
• insufficient or unfrequent laboratory follow-up; 
• competing T2DM-related co-morbidities and complications: obstructive sleep apnoea 
syndrome, chronic kidney disease or left ventricular dysfunction;  
• lack of patient empowerment and responsibility for self-care; 
• social pressures and discrimination related to aspects of diabetes management; 
• low socioeconomic or educational status; 
• unsupportive/overstretched healthcare systems. 
3. Residual vascular risk in T2DM 
RVR in T2DM is best defined as “the residual risk of incident vascular events or progression 
of established vascular damage persisting in patients treated with current evidence-based 
recommended care, including risk from established risk factors, such as dyslipidemia, high 
blood pressure, hyperglycemia, inflammation and unhealthy lifestyles, and risk related to 
emerging or newer risk factors” [4,5].  
Determining macro- and micro- RVR in T2DM patients after implementation of standards of 
care is especially relevant when dealing with a chronic condition in which a substantial 
fraction of risk remains addressable, eg. by further lowering of exposure levels to standards 
RFs for micro- and macroangiopathy. Besides those modifiable components to RVR, one 
should also consider in risk assessment non-gender, non-modifiable components of RVR in 
T2DM, such as ethnicity, certain polymorphisms, and familial histories for (i) premature-
onset CVD; (ii) obesity; and/or (iii) impaired glucose homeostasis or diabetes.  
For macrovascular RVR, the usual approach involves single-variable assessment (HbA1c, 
SBP and LDL-C) and targeting with TLC and/or pharmacotherapy. Due to an 
overwhelmingly glucocentric approach to T2DM management, the hierarchy of priorities 
follows a sequence in which hyperglycemia control ranks first, followed on a par with BP 
control and LDL-C lowering with statin as preferred agent, and then with a needs 
assessment for aspirin therapy as antiplatelet agent in high-risk patients [12-15].  
Combined assessment of the harmful effects of multiple coexisting modifiable variables on 
RVR is rarely done for an individual T2DM patient, even though multifactorial intervention 
was demonstrated to be highly-effective in reducing micro- and macrovascular RVR [22-24]. 
Various calculators were proposed to estimate absolute risk in nondiabetic and diabetic 
patients [25-31]. At present, the best means to predict macrovascular residual risk of CAD 
(nonlethal or lethal) and stroke (nonlethal or lethal) in patients in primary macrovascular 
prevention is the T2DM-specific calculator United Kingdom Prospective Diabetes Study 
(UKPDS) Risk Engine [25,27,28]. It computes risk from the following variables: (i) known 
T2DM duration, (ii) age, (iii) gender, (iv) ethnicity, (v) smoking status, (vi) atrial fibrillation, 
(vii) current HbA1c level, (viii) SBP, (ix) total cholesterol and (x) high-density lipoprotein 
cholesterol (HDL-C).  
In a diabetic RVR perspective, such calculations of absolute predicted risk should ideally be 
performed prior to, and following implementations of standards of care to control 
hyperglycemia, high BP and hypercholesterolemia, with updated levels as input for 
estimating the magnitude of risk reduction. Such an approach will yield relevant figures 
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regarding (i) absolute vascular risk for CAD (nonlethal or lethal) and stroke (nonlethal or 
lethal), (ii) RVR for CAD (nonlethal or lethal) and stroke (nonlethal or lethal), together with 
(iii) absolute and (iv) relative decreases in CAD (nonlethal or lethal) and stroke (nonlethal or 
lethal) risks [25,27,28].  
In order to illustrate RVR in T2DM from real-life conditions, we systematically assessed 
UKPDS Risk in 429 consecutive T2DM outpatients in primary macrovascular prevention. 
Eighty percent were White Caucasians, with a male-to-female ratio of 59:41. Mean age (1 
standard deviation [SD]) was 62 (12) years, and known diabetes duration 12 (8) years. 
Sixteen percent were current smokers. Major modifiable variables in this cohort receiving 
standards of care in an academic setting were: total cholesterol: 173 (39) mg/dL; HDL-C: 48 
(14) mg/dL; SBP: 137 (18) mmHg; and HbA1c: 7.6 (1.47)%. The 10-year UKPDS Risk Engine 
estimated RVR values are illustrated in Figure 1. For the entire cohort, 10-year risk of CAD 
was high (almost 20%), a level in accordance with the status of secondary-prevention equivalent 
proposed for T2DM in primary macrovascular prevention [1,2]. According to gender, male 
T2DM patients had a 62% higher absolute risk for CAD than female patients, although the 
difference between genders was less marked for fatal CAD or stroke, and abolished for fatal 
stroke, illustrating the loss of protective effects afforded by the female gender in T2DM. 
Despite their primary CVD prevention status, those 429 patients had a high prevalence of 
microangiopathies: 46% (any microangiopathy); 21% (retinopathy); 23% (peripheral 
neuropathy); and 36% (albuminuria). These figures highlight the complexity of defining 
RVR in diabetic patients, who may at any time belong to different risk categories according 
to (i) the micro- vs. macrovascular level of dichotomy, and (ii) which target organs are under 
scrutiny.  
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Fig. 1. UKPDS Risk Engine's 10-year prediction estimates for developing non-fatal and fatal 
coronary artery disease (CAD), fatal CAD, non-fatal and fatal stroke in T2DM patients of 
both gender (n=429; solid bars), both groups in primary cardiovascular prevention.The 
UKPDS Risk Engine computes the following variables, i.e. (1) known T2DM duration, (2) 
age, (3) gender, (4) ethnicity, (5) smoking status, (6) atrial fibrillation, (7) HbA1c level, (8) 
systolic BP, (9) total cholesterol (C) and (10) HDL-C. 
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With respect to microangiopathy, individual RVR assessment is limited to an “educated 
guess” relating hyperglycemia exposure time (with known diabetes duration as surrogate) to 
hyperglycemia severity (with current HbA1c as surrogate). Unfortunately, there exists no 
assigned microvascular calculator available for estimating 10-year absolute risk in major 
target organs, such as retina, kidney or peripheral nerves destined to diabetic patients or to 
prediabetic patients with rapid loss of β-cell function and as such at very high risk for new-
onset T2DM. Such a limitation in microangiopathic RVR represents a truly unmet need for 
T2DM management. Such is also the case when it comes to estimating absolute RVR in end-
organs at risk for combined micro- and macroangiopathies, such as PAD in lower limbs, 
cerebrovascular disease, certain subtypes of nephropathy, or erectile dysfunction. Other 
limitations of current risk calculators for T2DM patients include: (i) the complexity of the 
underlying pathophysiological processes; (ii) the poor predictive value of 
(micro)albuminuria as surrogate to diabetes-related nephropathy; (iii) the lack of effective 
clinical surrogate for early-neuropahy; and (iv) the exclusion of familial histories for 
diabetes, early-onset CVD, obesity and/or IR and of their mutual metabolic/vascular 
impacts [25-32]. 
4. Atherogenic dyslipidemia 
A major component of modifiable RVR is lipid-related, both associated with LDL and non-
LDL, including atherogenic dyslipidemia (AD). Epidemiological studies and landmark 
intervention trials clearly established that AD contributes to RVR for macrovascular disease 
in T2DM, even when LDL-C and/or hyperglycemia are controlled at baseline. The hallmark 
of AD is raised fasting TG and low HDL-C levels, two routinely available markers of a series 
of complex and deleterious metabolic abnormalities which affect, in a proatherogenic way, 
LDL and non-LDL lipoproteins composition and numbers. These abnormalities also 
diminish, in an antiatherogenic way, the dynamics and magnitude of reverse cholesterol 
transport [33-45].  
The underlying process driving AD in T2DM or nondiabetic patients consists of (i) 
overproduction by the liver of TG-rich, apolipoprotein B100(apoB)-carrying lipoproteins of 
the very-low density lipoprotein (VLDL) class, as a direct result of (ii) whole body IR and 
compensatory hyperinsulinemia, leading to (iii) raised portal insulin levels, which affect (iv) 
VLDL assembly and export by the hepatocyte, as a consequence of preserved insulin 
sensitivity of select pathways for lipogenesis and TG-rich lipoproteins synthesis 
[33,34,36,37,41,45].   
Screening for AD provides a clinically-relevant and easy means to capture RVR associated 
with low HDL-C, high TG and their determinants. Such screening is not routinely 
performed due eg. to lack of general agreement on criteria or cut-offs based on current vs. 
baseline HDL-C and TG values. One way to diagnose AD consists of establishing the 
combined occurrence of high TG levels and low HDL-C. This seemingly easy estimation is 
rarely performed as such, due to (i) lack of consensual cut-off values across gender, 
race/ethnicities or underlying conditions; (ii) the requirement for baseline lipid values 
(prior to lipid-lowering drugs (LLD)); and (iii) the limiting fact that a sine qua non co-
occurrence definition does not take into account the linearity of these non-LDL 
abnormalities, since both HDL-C and TG are continuous CVD risk variables 
[35,38,39,40,42,44,45]. Such an approach based on co-occurrence may also underestimate 
AD prevalence and severity in T2DM subpopulations with spontaneously low (Afro-
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Americans, sub-Saharan Africans) or elevated TG levels [46-48]. A more rationale 
approach would be to use ratios between TG and HDL-C in order to incorporate each 
component’s information as continuous variable while increasing the epidemiological 
potency by having the atherogenic TG variable as numerator together with the anti-
atherogenic HDL-C as denominator [35,38,39,40,45]. We showed that log(TG)/HDL-C is a 
simple means to estimate AD and the residual CV risk it confers to T2DM patients. Thus, 
this AD surrogate ratio was associated with major cardiometabolic and glucose 
homeostasis determinants, as well as with poorer metabolic control, and related to 
macroangiopathy prevalence and estimated UKPDS CAD risk [44]. 
5. Metabolic syndrome 
Low HDL-C and high TG are part of the MetS definition, either as individual AD 
component or in combination. The presence of a MetS phenotype or its score (from 0/5 to 
5/5) is another simple means to capture RVR. Identifying a MetS phenotype may be used as 
a dichotomic state (presence vs. absence). In addition, score ranking within MetS syndrome 
categories, besides providing a stepwise surrogate for IR/hyperinsulinemia, also provides a 
simple means to determine increasing CV risk categories (from 1/5 to 5/5 for T2DM 
patients). While the MetS is not an absolute risk calculator, its presence hints to heightened 
relative RVR, as a result of exposure to standard CV RFs (underlying the current definition, 
such as hypertension and hyperglycemia) or due to the presence of AD. MetS ranking is also 
associated with lesser target achievement for key variables, such as HbA1c, SBP or LDL-C. In 
addition, the MetS also associates with microangiopathy prevalence in major target organs 
[18,49-55].  
6. New and emerging risk markers and factors 
Many candidates RFs were proposed in the last decades to improve CVD risk assessment 
or RVR appraisal, although few, if any, are globally acknowledged in guidelines as part of 
standards of care and follow-up. These candidate RFs include eg. biological markers of 
low-grade subclinical systemic inflammation, markers of plaque instability, of endothelial 
dysfunction, or of proatherothrombotic conditions. None of these emerging markers/RFs 
are at present used as input variables in CVD risk calculators. Other emerging RFs for risk 
assessment in T2DM include potentially modifiable variables contributing to, or 
associated with RVR, such as the MetS phenotype, IR /hyperinsulinemia, adverse lifestyle 
habits (excessive caloric intake, Westernized diets, smoking, high ethanol intake, 
sedentarity), high-cardiometabolic risk anthropometrics (abnormal 
distribution/expansion of fat tissue, sarcopenia), or other comorbidites increasingly 
described as associated with the common form of T2DM (sleep-related breathing 
disorders, chronic kidney disease, left ventricular systolic/diastolic dysfunction, or non-
alcoholic fatty liver disease) [56-74].  
Table 1 enumerates a non-exhaustive series of non-modifiable and modifiable markers/RFs 
for micro-/macroangiopathy which may be at play in accruing RVR in T2DM patients, 
including inflammatory, behavioural/environnemental, and proatherothrombotic, whereas 
Table 2 lists markers/RFs related to lipids and lipoproteins or to cardiometabolic factors 
involved in T2DM-related RVR [45,56-74].  
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age platelet activity
male gender platelet agregation
ethnicity platelet size / volume
family history: aspirin resistance
      early-onset CVD lipoprotein(a)
      overweight / obesity fibrinogen
      IFG / IGT / T2DM factor V, VII, and VIII
former tobacco smoking fibrinopetide A
small size at birth for gestational age PAI-1
right handedness prothrombin fragments 1 + 2
genes / loci and polymorphisms associated with: tissue-plasminogen activator
      CVD von Willebrand factor antigen
      β -cell function loss D-dimer
      overweight / obesity
cystatin-C
high-sensitivity C-reactive protein asymmetric dimethylarginine
leucocyte count nongenetic causes of iron overload
interleukin-6 hemochromatosis
matrix metalloproteinase 9 elevated ferritinaemia
serum amyloid A Nt-proANP and Nt-proBNP
soluble CD40 ligand endothelin-1
vascular / cellular adhesion molecules urotensin II
lipoprotein-associated phospholipase A(2) Cytomegalovirus, Herpes simplex virus
periodontal disease Helicobacter pylori
Chlamydia pneumoniae
collagen vascular disease
current tobacco smoking non-specific ST-segment ECG changes
air pollution (including airborne fine particles) coronary artery calcifications
sedentary lifestyle (surrogate : TV viewing) left ventricular dysfunction
physical inactivity obstructive sleep apnoea / hypopnoea syndrome
quantitative  / qualitative sarcopenia psoriasis
psychosocial stress rheumatoid arthritis
low socioeducative status systemic lupus erythematosis
low income HIV infection on highly-active antiretroviral therapy
decreased fruit and vegetable consumption hypoglycemia unawareness
*: see Table 2 for lipid and cardiometabolic risk factors. ANP: Atrial natriuretic peptide; BNP: brain natriuretic peptide;
CVD: cardiovascular disease; ECG: electrocardiogram; eGFR: estimated glomerular filtration rate; HIV: human
immunodeficiency virus; IFG: impaired fasting glucose; IGT: impaired glucose tolerance; NAFLD: nonalcoholic fatty
liver disease; PAI-1: plasminogen activator inhibitor type 1; T2DM type 2 diabetes mellitus; TV: television.   
Non-modifiable
Varia
Behavioural / environnemental
Coagulation - haemostasis - platelets
Inflammatory
 
Table 1. Micro or macrovascular disease risk factors/markers in T2DM patients: standard, 
emerging and candidate 
7. Reducing residual vascular risk in T2DM 
a. Targets attainment.  
Reducing RVR must be part of a continuum in managing individual patients. RVR 
assessment is the next logical step after implementation of good clinical practices. Despite 
RFs identification and standards of care provision, all major modifiable RFs rarely attain all 
recommended targets for a given individual in real-life conditions [12-17,21-24]. This 
supports a more global approach to further reduce RVR [4-6,75-84]: 
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total cholesterol overweight - obesity (surrogate : increased BMI)
LDL-C central fat distribution (surrogate : enlarged waist)
apolipoprotein B100 hypertension
non-HDL-C metabolic syndrome (presence vs . absence)
LDL particles number metabolic syndrome (score : 3/5 - 4/5 - 5/5) 
hypo-HDL-cholesterolaemia insulin resistance / hyperinsulinaemia
decreased apolipoprotein A-I dysadipokinemia (adiponectin, resistin, etc …)
HDL subtypes distribution non-alcoholic fatty liver / steatohepatitis / NAFLD
fasting hypertriglyceridemia chronic hyperglycaemia (surrogate : elevated HbA1c)
postprandial hypertriglyceridemia endothelial dysfunction
TG-rich lipoprotein remnants erectile dysfunction
apolipoprotein CIII(+)-carrying apoB lipoproteins (micro)albuminuria
oxidized LDL glomerular hyperfiltration
antibodies to oxidized LDL CKD - eGFR <60 ml/min/1.73 m
2 
small-dense LDL end-stage renal failure / dialysis
lipoprotein(a) hyperuricemia
lipoproteins glycation hyperhomocysteinemia
lipoprotein receptors glycation vitamin D deficiency
lipid metabolism enzymes glycation sympathetic nervous system hyperactivity
Apo: apolipoprotein; BMI: body mass index; C: cholesterol; CKD: chronic kidney disease; CVD: cardiovascular disease;
eGFR: estimated glomerular filtration rate; HbA1c: glycated haemoglobin; HDL: high-density lipoprotein; LDL: low-
density lipoprotein; NAFLD: nonalcoholic fatty liver disease; T2DM type 2 diabetes mellitus; TG: triclycerides
(triacylglycerols).   
Lipids and lipoproteins Cardiometabolic
 
Table 2. Lipid, lipoproteins and cardiomatabolic micro- and macrovascular disease risk 
factors/markers in TD2M patients: standard, emerging and candidate 
1. continuous strive towards conventional target attainment, including reinforcement of 
TLC, higher drug dosages, drug switches  or combination therapies; 
2. addressing identified barriers to chronic diseases management using an individualized 
patient-based approach; 
3. force-driving major modifiable RFs below recommended thresholds or physiological 
ranges (“the lower is better” paradigm); 
4. impacting upon emerging risk factors, but this often means venturing beyond 
guidelines, or using off-label medications, or resorting to newer therapies not always 
supported by evidence from randomized clinical trials.  
b. Non-LDL dyslipidemia and macroangiopathic RVR 
As regards non-LDL dyslipidemia, AD can be improved by TLC, fibrates, or nicotinic acid 
[45,85-93]. In T2DM, data from the recent Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) Lipid trial reinforce the residual risk hypothesis for macroangiopathy, since 
despite achieving a mean LDL-C of 80 mg/dl, patients in the pre-specified subgroup with 
AD (defined as having both baseline TG ≥204 mg/dl and baseline HDL-C ≤34 mg/dl; 
numbering 17% of the ACCORD cohort) experienced a 70% higher relative rate (7% higher 
absolute rate) of incident major CV events (composite of CVD death, nonfatal myocardial 
infarction and nonfatal stroke) over a mean 4.7 year follow-up when compared to patients 
without AD [94,95].  
In ACCORD Lipid, although in the whole T2DM cohort the main macrovascular outcome 
was negative, a prespecified subgroup of T2DM patients with AD treated with combination 
LLD therapy [simvastatin plus fenofibrate] had a 31% reduction in major CV events, 
compared to those treated with simvastatin alone (12.4% incidence [simvastatin plus 
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fenofibrate] vs. 17.3% [simvastatin monotherapy]), amounting to a 5% absolute RVR 
reduction. The number-needed-to-treat was low, calculated at 20 T2DM patients with AD 
receiving LLD biotherapy over 5 years to prevent one major CV event. This number 
compares very favourably with those from landmark intervention trials with LLD in 
diabetic or nondiabetic populations. When primary outcome in the whole cohort was 
analyzed according to gender, another prespecified analysis, data for men showed a strong 
indication that they benefited from combination therapy (11.2% [fenofibrate] vs. 13.3% 
events [placebo]), while data for women were not as conclusive. Thus, whereas the P value 
for interaction related to gender was significant (0.0106), the confidence interval of the effect 
in females (9.1% [fenofibrate] vs. 6.6% events [placebo]) was not only wide, but also 
encroached the line of unity.  
In ACCORD, AD was present in only one-sixth of the population under study, a subgroup 
which however markedly benefited in terms of macrovascular RVR reduction from 
combined therapy [94,95]. Whether in real-life conditions a higher proportion of T2DM 
patients might benefit from combination therapy [simvastatin plus fenofibrate] as a result of 
having AD as a comorbidity, is a tentative hypothesis. In ACCORD Lipid, the low recorded 
AD prevalence was a result not only of inclusion criteria, sequential exclusion of tertiles, 
intrinsic characteristics of the study population, and a relatively high proportion of 
volunteers of Afro-American ethnicity, who often have naturally low-to-normal 
triglycerides levels and less prone to suffer from AD [46-48].  
We sought to investigate whether AD prevalence was akin to that observed in the ACCORD 
Lipid trial in an unselected, mostly Caucasian T2DM patients sample (n=974), consecutively 
attending our academic diabetes clinic. As ACCORD Lipid cutoffs, based on study-specific 
tertiles are unapplicable to other T2DM populations, we selected another approach to define 
AD, based on the co-occurrence of low HDL-C and high TG, with cutoffs derived from the 
harmonized definition of the MetS [51,53,55]. We also checked patient’s file in order to 
retrieve pre-LLD HDL-C and TG values in patients on lipid-lowering drug(s), in order to 
establish the true, unbiased presence of AD (Table 3).  
With such criteria and stringent use of baseline lipids values, we observed a higher 
prevalence of AD (35%), similar in both genders. In our survey, mean pre-LLD triglycerides 
were 203 mg/dl vs. 167 mg/dl for current values, representing an average difference of 36 
mg/dl (18%), a difference sufficient to otherwise underestimate AD prevalence unless pre-
LLD TG values are available. Such a confounding effect of LLD was not observed as regards 
HDL-C. In this analysis, the expected differences in the general population between genders 
were observed for HDL-C and apolipoprotein A-I level. Female patients also had 
significantly higher total cholesterol and significantly lower AD ratio [log(TG)/HDL-C] 
levels (Table 3).  
Whatever AD prevalence data, notwithstanding the beneficial effects of fenofibrate on 
microvascular residual risk, a substantial proportion of unselected T2DM patients may 
potentially benefit from combination therapy to substantially decrease a modifiable 
component of AD-related RVR [94,95]. Such a likely assumption needs however to be 
confirmed from both epidemiological sources documenting the real-life prevalence of AD, 
and also from prospective randomised controlled trials, in which only fenofibrate-naïve 
patients with untreated AD would be included, with AD defined by consensual criteria, 
such as MetS thresholds for non-LDL dyslipidemia or trial-dependent AD cutoffs derived a 
posteriori on tertiles of non-LDL lipids at study entry such as in ACCORD Lipid [45]. Future 
trial should also investigate whether triple therapy (simvastatin plus fenofibrate plus 
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nicotinic acid), aimed at further correction of most aspects of hypercholesterolemia and AD, 
will provide proportionate benefit for RVR in T2DM.  
 
p
   n
  atherogenic dyslipidemia * % NS
  pre-LLD  total cholesterol mg.dl
-1
230 ( 43 ) 225 ( 42 ) 240 ( 43 ) <0.0001
  pre-LLD  LDL-C mg.dl
-1
145 ( 35 ) 143 ( 35 ) 150 ( 35 ) 0.0170
  pre-LLD  HDL-C mg.dl
-1
47 ( 13 ) 45 ( 12 ) 52 ( 15 ) <0.0001
  pre-LLD  TG mg.dl
-1
203 ( 167 ) 201 ( 155 ) 208 ( 193 ) NS
  anti-dyslipidemic drug(s) % NS
      statin - fenofibrate - ezetimibe % NS
  total cholesterol mg.dl
-1
179 ( 43 ) 175 ( 42 ) 186 ( 44 ) 0.0001
  non-HDL-C mg.dl
-1
132 ( 42 ) 130 ( 41 ) 135 ( 42 ) NS
  apolipoprotein B100 mg.dl
-1
90 ( 27 ) 89 ( 27 ) 92 ( 27 ) NS
  LDL-C mg.dl
-1
99 ( 35 ) 98 ( 35 ) 102 ( 36 ) NS
  HDL-C mg.dl
-1
47 ( 14 ) 44 ( 13 ) 52 ( 15 ) <0.0001
  apolipoprotein A-I mg.dl
-1
149 ( 30 ) 143 ( 28 ) 163 ( 31 ) <0.0001
  triglycerides mg.dl
-1
167 ( 120 ) 171 ( 128 ) 161 ( 105 ) NS
  log (TG).HDL-C
-1
0.051 ( 0.025 ) 0.054 ( 0.026 ) 0.046 ( 0.021 ) <0.0001
Mean (1 SD) values; * : atherogenic dyslipidemia was defined as the concurrence of low HDL-C (<40 mg/dl in males; <50 mg/dl in
females) and elevated fasting triglycerides (>150 mg/dl in both genders) as defined by the NCEP-ATP III cutoffs used to define the
discrete lipid components of the metabolic syndrome score. Lipid values used to define AD were baseline (pre-LLD) lipids levels in
patients treated with LLD(s). HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; LLD: lipid-
lowering drug(s); T2DM: type 2 diabetes mellitus; TG: triglycerides. p: statistical value from Student's t test; NS: not significant (p value
= or > 0.05).   
females
65
both genders
974 337
35
63
51 - 18 - 3
35
53 - 21 - 3
males
637
66
55 - 22 - 3
35
 
Table 3. Atherogenic dyslipidemia prevalence, lipid-lowering drug(s) therapy, and baseline 
vs. current lipids and lipoproteins values in unselected T2DM patients 
c. Microangiopathic residual vascular risk 
Diabetic eye disease includes diabetic retinopathy (DRP) and non-vessel comorbidities, such 
as cataract or glaucoma [96]. DRP is a microangiopathy affecting the retinal blood vessels 
resulting predominantly from poor metabolic control, which produces microvascular 
occlusion and leakage, leading to progressive retinal damage which may end in complete 
visual loss as a result of maculopathy or ischemic/proliferative retinopathy [96-100]. Few 
modifiable risk factors are identified with respect to DRP: poor metabolic (i.e. glycemic) 
control; hypertension, especially if poorly-controlled; LDL and non-LDL dyslipidemia; 
anemia and possibly, tobacco smoking. The recently published ACCORD Eye substudy 
highlighted the limits of conventional approaches based on near-normalization of two key 
modifiable variables (HbA1c and high blood pressure). In ACCORD, DRP outcomes were 
defined as a ≥3-steps DRP progression on the EDTRS scale, or development of DRP 
requiring laser therapy or vitrectomy [101-103].  
While glycemic control intensification significantly reduced the rate of progression of DRP 
(by a relative 33% and an absolute 3.1%, respectively), it was associated with serious safety 
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concerns, as higher all-cause mortality was observed in the intensive glycemic control group 
[104]. This led to premature termination of the glycemic arm of the ACCORD trial. Another 
source of disappointment from the ACCORD trial for microvascular RVR reduction was the 
lack of efficacy of BP normalization to improve primary DRP outcomes [105]. These findings 
highlights the current pitfalls of current approaches to DRP management based on a “the 
lower the better” paradigm for the two major standard modifiable risk factors, i.e. HbA1c and 
BP [104].  
As regards lipids, landmark statin trials in T2DM or in subgroups with T2DM failed to 
identify a beneficial effect of LDL- lowering on any type on diabetic microangiopathies. On 
the other hand, epidemiological evidence links AD with RVR for diabetic retinopathy 
and/or nephropathy in T2DM [4-6,100,104]. The REsiduAl risk, Lipids and Standard Therapies 
(REALIST) studies are two Residual Risk Reduction Initiative-initiated worldwide 
epidemiological retrospective case-control surveys designed to assess AD-related macro- 
and microvascular residual risk. These are performed in non-diabetic and T2DM patients 
(REALIST MICRO) receiving current standards of care, with LDL-C levels at or near goal, 
treated or not with a statin. Pilot results from REALIST MICRO show a highly-significant 
and strong association between AD and microangiopathy incidence, even when LDL-C is 
controlled [107,108].  
In the ACCORD Eye substudy, fenofibrate decreased RVR of DRP progression, assessed 
using the validated EDTRS scale, and irrespective of baseline lipids. The efficacy of 
fenofibrate was most obvious in patients with DRP at baseline, i.e. those in secondary DRP 
prevention [101-104]. Such a beneficial effect confirms the previously documented benefits 
of fenofibrate on DRP. This, in the Fenofibrate Intervention and Event Lowering in Diabetes 
(FIELD) study, a previous other large randomised controlled trial, a decreased requirement 
for DRP-related laser therapy was observed in T2DM treated with fenofibrate (vs. placebo). 
Such decreased requirement was however neither a primary outcome endpoint nor a “hard 
endpoint” for DRP progression assessment [88,104,106].  
Results from ACCORD Eye therefore markedly raise the level of clinical evidence for a 
beneficial effect of this PPAR-ǂ agonist on DRP. The FIELD study also showed that 
fenofibrate decreased new-onset albuminuria and diabetes-related non-traumatic 
amputations in T2DM patients [109]. In a recent assessment of fenofibrate's renal effects 
(FIELD washout sub-study), decreased albuminuria and reduced estimated glomerular 
filtration rate (eGFR) loss over 5 years were observed in patients allocated to the fenofibrate 
arm [110]. These observations confirm that fenofibrate not only reduces albuminuria or 
delay its onset, but also diminishes the natural history of progressive eGFR impairment in 
T2DM, despite an early and reversible increase in plasma creatinine [104,110-114]. As 
regards other LLD, future trials will establish whether targeting low HDL-C with nicotinic 
acid, alone or on top of background statin, reduces RVR of macroangiopathy in high-risk 
T2DM patients [90-93,115]. Safe and effective combination of LLDs (bi- or tritherapies) 
targeting most aspects of dyslipidemia are likely to become standards of care in high-risk 
populations such as patients with T2DM [45,75,91,104,115-118].  
8. Benchmarking 
Innovative approaches are needed to improve individual and overall target achievement 
with the aim of reducing RVR. Benchmarking targeting physicians is one of those newer 
approaches. The goal of the non-interventional randomised OPTIMISE trial was to 
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investigate in 6 European countries the effect of physician’s benchmarking on quality of 
care, assessed according to the percentage of T2DM patients achieving pre-set targets for 
three key modifiable variables (HbA1c, LDL-C and SBP), as recommended by international 
guidelines. At baseline, the percentage of patients achieving targets was highly 
unsatisfactory: 51% (HbA1c); 27% (SBP); and 35% (LDL-C), with a mere 5% reaching all three 
targets at study entry. Physicians were randomly assigned to receive either benchmarked 
feedback or non-benchmarked feedback on their patients’ modifiable outcome indicators 
(HbA1c, fasting glycaemia, total cholesterol, HDL-C, LDL-C and TG). At study end, the 
percentage of patients achieving all targets almost doubled, suggesting that benchmarking 
may be an innovative approach to improve target attainment of modifiable variables 
affecting RVR in T2DM patients [21,119,120]. 
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